Sodium cromoglicate inhalant - AZTherapies

Drug Profile

Sodium cromoglicate inhalant - AZTherapies

Alternative Names: ALZT OP1a; Cromolyn - AZTherapies; Sodium cromoglicate - AZTherapies

Latest Information Update: 04 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AZTherapies
  • Class Antiallergics; Antiasthmatics; Antihyperglycaemics; Antitussives; Benzopyrans; Chromones; Nootropics; Skin disorder therapies; Small molecules
  • Mechanism of Action Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Cognition disorders

Most Recent Events

  • 04 Aug 2017 Chemical structure information added
  • 04 Jul 2017 AZTherapies has patent protection for cromolyn derivatives and its preparation for imaging and therapeutic applications
  • 26 Jun 2017 Clinical trials in Cognition disorders (Adjuvant therapy) in USA prior to June 2017 (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top